Oral versus vaginal combined hormonal contraceptives' effect on coagulation and inflammatory biomarkers among young adult women

Afshin A. Divani; Xianghua Luo; Kyle R. Brandy; Rachel M. Meyer; Marilyn S. Joseph; James D. Flaherty; Gundu H.R. Rao; Yvonne H. Datta

doi:10.1177/1076029612440036

Oral versus vaginal combined hormonal contraceptives' effect on coagulation and inflammatory biomarkers among young adult women

Afshin A. Divani, Xianghua Luo, Kyle R. Brandy, Rachel M. Meyer, Marilyn S. Joseph, James D. Flaherty, Gundu H.R. Rao, Yvonne H. Datta

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

In order to compare the effect of combined oral contraceptive (COC) and combined vaginal contraceptive (CVC) methods on the inflammation and procoagulation, we recruited female participants in 3 groups: control participants, COC users, and CVC users. We measured different blood biomarkers. The users of both COC and CVC had higher levels of C-reactive protein (P <.0001) and factor VII (P <.0001). However, CD40 ligand was only higher for COC users (P <.0001) and not the CVC users. Even though the levels of thrombin/antithrombin III were not higher for COC and CVC users, as compared to the controls, CVC users had higher levels as compared to COC users (P =.0327). As compared to the control group, we observed higher levels von Willebrand factor among CVC users but not the COC users. Longitudinal studies with larger sample size are needed to better assess the inflammatory and procoagulation response due to CVC use.

Original language	English (US)
Pages (from-to)	487-494
Number of pages	8
Journal	Clinical and Applied Thrombosis/Hemostasis
Volume	18
Issue number	5
DOIs	https://doi.org/10.1177/1076029612440036
State	Published - Sep 2012

Bibliographical note

Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the Office of the Vice President for Research and Minnesota Medical Foundation at the University of Minnesota, Minneapolis, MN.

Keywords

blood biomarkers
hormonal contraceptives
inflammation
prothrombotic
risk factors
thrombosis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1177/1076029612440036

OpenUrl availability

Full text

Cite this

@article{6de81b67e299408682328f467f2eebca,

title = "Oral versus vaginal combined hormonal contraceptives' effect on coagulation and inflammatory biomarkers among young adult women",

abstract = "In order to compare the effect of combined oral contraceptive (COC) and combined vaginal contraceptive (CVC) methods on the inflammation and procoagulation, we recruited female participants in 3 groups: control participants, COC users, and CVC users. We measured different blood biomarkers. The users of both COC and CVC had higher levels of C-reactive protein (P <.0001) and factor VII (P <.0001). However, CD40 ligand was only higher for COC users (P <.0001) and not the CVC users. Even though the levels of thrombin/antithrombin III were not higher for COC and CVC users, as compared to the controls, CVC users had higher levels as compared to COC users (P =.0327). As compared to the control group, we observed higher levels von Willebrand factor among CVC users but not the COC users. Longitudinal studies with larger sample size are needed to better assess the inflammatory and procoagulation response due to CVC use.",

keywords = "blood biomarkers, hormonal contraceptives, inflammation, prothrombotic, risk factors, thrombosis",

author = "Divani, {Afshin A.} and Xianghua Luo and Brandy, {Kyle R.} and Meyer, {Rachel M.} and Joseph, {Marilyn S.} and Flaherty, {James D.} and Rao, {Gundu H.R.} and Datta, {Yvonne H.}",

note = "Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the Office of the Vice President for Research and Minnesota Medical Foundation at the University of Minnesota, Minneapolis, MN.",

year = "2012",

month = sep,

doi = "10.1177/1076029612440036",

language = "English (US)",

volume = "18",

pages = "487--494",

journal = "Clinical and Applied Thrombosis/Hemostasis",

issn = "1076-0296",

publisher = "SAGE Publications Inc.",

number = "5",

}

TY - JOUR

T1 - Oral versus vaginal combined hormonal contraceptives' effect on coagulation and inflammatory biomarkers among young adult women

AU - Divani, Afshin A.

AU - Luo, Xianghua

AU - Brandy, Kyle R.

AU - Meyer, Rachel M.

AU - Joseph, Marilyn S.

AU - Flaherty, James D.

AU - Rao, Gundu H.R.

AU - Datta, Yvonne H.

N1 - Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the Office of the Vice President for Research and Minnesota Medical Foundation at the University of Minnesota, Minneapolis, MN.

PY - 2012/9

Y1 - 2012/9

N2 - In order to compare the effect of combined oral contraceptive (COC) and combined vaginal contraceptive (CVC) methods on the inflammation and procoagulation, we recruited female participants in 3 groups: control participants, COC users, and CVC users. We measured different blood biomarkers. The users of both COC and CVC had higher levels of C-reactive protein (P <.0001) and factor VII (P <.0001). However, CD40 ligand was only higher for COC users (P <.0001) and not the CVC users. Even though the levels of thrombin/antithrombin III were not higher for COC and CVC users, as compared to the controls, CVC users had higher levels as compared to COC users (P =.0327). As compared to the control group, we observed higher levels von Willebrand factor among CVC users but not the COC users. Longitudinal studies with larger sample size are needed to better assess the inflammatory and procoagulation response due to CVC use.

AB - In order to compare the effect of combined oral contraceptive (COC) and combined vaginal contraceptive (CVC) methods on the inflammation and procoagulation, we recruited female participants in 3 groups: control participants, COC users, and CVC users. We measured different blood biomarkers. The users of both COC and CVC had higher levels of C-reactive protein (P <.0001) and factor VII (P <.0001). However, CD40 ligand was only higher for COC users (P <.0001) and not the CVC users. Even though the levels of thrombin/antithrombin III were not higher for COC and CVC users, as compared to the controls, CVC users had higher levels as compared to COC users (P =.0327). As compared to the control group, we observed higher levels von Willebrand factor among CVC users but not the COC users. Longitudinal studies with larger sample size are needed to better assess the inflammatory and procoagulation response due to CVC use.

KW - blood biomarkers

KW - hormonal contraceptives

KW - inflammation

KW - prothrombotic

KW - risk factors

KW - thrombosis

UR - http://www.scopus.com/inward/record.url?scp=84871816714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871816714&partnerID=8YFLogxK

U2 - 10.1177/1076029612440036

DO - 10.1177/1076029612440036

M3 - Article

C2 - 22431858

AN - SCOPUS:84871816714

SN - 1076-0296

VL - 18

SP - 487

EP - 494

JO - Clinical and Applied Thrombosis/Hemostasis

JF - Clinical and Applied Thrombosis/Hemostasis

IS - 5

ER -

Oral versus vaginal combined hormonal contraceptives' effect on coagulation and inflammatory biomarkers among young adult women

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this